From NASS: New Bone Graft Substitute for Orthofix

Orthofix International recently released its Collage Osteoconductive Scaffold, a new bone graft substitute or use in spine and orthopedic indications.

The rollout came during the North American Spine Society (NASS) meeting annual meeting held in Chicago, Ill.

According to the company the new synthetic platform is based on “highly-purified biocompatible materials of ss-TCP and type-1 collagen.”

Michael Finegan, president of the firm’s Biologics unit said the company would begin to focus on broadening its portfolio of biologic products.

“The synthetic segment of the market is large, attractive, and presents a perfect complement to our existing biologic portfolio,” he said.

The U.S. market for synthetic bone graft substitutes is estimated to include more than 320,000 procedures and is valued at approximately $360 million annually, according to a recent iData Research report.

Orthofix International is based outside Dallas, Texas.